- Home
- QNRX vs ACON Comparison
QNRX vs ACON Comparison
Compare QNRX & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- ACON
- Stock Information
- Founded
- QNRX 2018
- ACON 2008
- Country
- QNRX United States
- ACON United States
- Employees
- QNRX N/A
- ACON N/A
- Industry
- QNRX Medical/Dental Instruments
- ACON Retail: Computer Software & Peripheral Equipment
- Sector
- QNRX Health Care
- ACON Technology
- Exchange
- QNRX Nasdaq
- ACON Nasdaq
- Market Cap
- QNRX 4.8M
- ACON 4.4M
- IPO Year
- QNRX N/A
- ACON 2022
- Fundamental
- Price
- QNRX $15.56
- ACON $8.31
- Analyst Decision
- QNRX
- ACON Buy
- Analyst Count
- QNRX 0
- ACON 2
- Target Price
- QNRX N/A
- ACON $22.00
- AVG Volume (30 Days)
- QNRX 850.8K
- ACON 393.5K
- Earning Date
- QNRX 11-06-2025
- ACON 11-13-2025
- Dividend Yield
- QNRX N/A
- ACON N/A
- EPS Growth
- QNRX N/A
- ACON N/A
- EPS
- QNRX N/A
- ACON N/A
- Revenue
- QNRX N/A
- ACON $62,948.00
- Revenue This Year
- QNRX N/A
- ACON $145.39
- Revenue Next Year
- QNRX N/A
- ACON $145.45
- P/E Ratio
- QNRX N/A
- ACON N/A
- Revenue Growth
- QNRX N/A
- ACON 16.68
- 52 Week Low
- QNRX $5.01
- ACON $6.20
- 52 Week High
- QNRX $54.95
- ACON $3,499.51
- Technical
- Relative Strength Index (RSI)
- QNRX 66.15
- ACON 52.20
- Support Level
- QNRX $12.31
- ACON $7.60
- Resistance Level
- QNRX $41.80
- ACON $12.03
- Average True Range (ATR)
- QNRX 3.40
- ACON 0.72
- MACD
- QNRX 0.95
- ACON 0.08
- Stochastic Oscillator
- QNRX 24.75
- ACON 22.05
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.